Results of Part A of KALAHARI, a Phase 2 Trial of THR-149, a plasma kallikrein inhibitor, for the treatment of diabetic macular oedema

Activity: Talk or presentation › Oral presentation

Period2 Sept 2022
Event titleEURETINA: Annual congress
Event typeConference
LocationHamburg, GermanyShow on map
Degree of RecognitionInternational